Phivida Holdings Inc. (CSE:VIDA)(CSE:VIDA.CN)(CNSX:VIDA) has appointed a Clinical Advisory Team comprised of leading health care practitioners and researchers from the United States and Canada. The Phivida clinical advisory team convened at the A4M Congress in Las Vegas, where Phivida launched Vida+ – its professional line of clinical grade products.
The Phivida Clinical Advisory Team are:
Dr. Sunil Pai, MD
Dr. Pai is an internationally recognized an expert in Integrative Medicine, a health activist/influencer and thought leader in the wellness industry. He is one of first formally Fellowship trained Integrative Medicine MD’s in the U.S. and has been trained in Family Medicine, Ayurvedic Medicine, Neuro & Medical Acupuncture, Homotoxicology, Physiological Regulating Medicine and Plant Based Nutrition. He specializes in formulation of natural products from raw materials to manufacturing and following them through to clinical studies. Author of Inflammation Nation – chosen by Kirkus Reviews to be listed in the Best of 2016 Indie Books. His most recent lectures at medical conferences include The Role of Plant Based Diets and Natural Anti-Inflammatories for Preventing, Treating and Reversing Chronic Diseases and CancerCannabinoid Medicine From Industrial Hemp Oil: Another Practical and Legal Cannabidiol (CBD) Alternative; and Inflammation and its effects on vascular pathology and chronic disease: PEMF application in Integrative Medicine.
Dr. Joost Luecker, PhD
Dr. Luecker has a PhD in plant science and an MSc in plant breeding and crop protection. He has over 17 years of research experience in biochemistry, botany, secondary metabolism in plants, molecular biology, and plant breeding at a variety of international universities, and has published multiple peer reviewed research papers in international plant and biochemistry journals. He also has experience as a Quality Assurance consultant in governmentally regulated industries.
Dr. Chris D. Meletis, ND
Dr. Meletis is an educator, international author and lecturer who has authored 16 books and over 200 national scientific articles in such journals and magazines as Natural Health, Alternative and Complementary Therapies, Townsend Letter for Doctors and Patients, Life Extension and Natural Pharmacy. Dr. Meletis is a former Dean of Naturopathic Medicine and was Chief Medical Officer for seven years. He was named the 2003 physician of the year by the American Association of Naturopathic Physicians. He has a deep passion for helping the underprivileged and spearheaded the creation of 16 free natural medicine healthcare clinics in the Portland metropolitan area of Oregon. He serves on several scientific advisory boards for the nutraceutical industry educating healthcare professionals internationally on the latest innovations, scientific research and clinical applications of natural products to support the innate healing and rebalancing capacity of the human body.
Dr. Brian Martin, ND
Dr. Martin holds a Bachelor of Science Degree (BSc) in Biology and a Chemistry Naturopathic Doctorate Degree (ND) from the National College of Naturopathic Medicine in Portland, Oregon and completed his practicum at East Moreland Hospital Emergency Ward. He is the founder of the NaturoMed Health Clinic and the EnerChanges. Diplomate in Anti-Aging Medicine from American Academy of Anti-Aging Medicine (A4M) and is board-certified in Chelation Therapy. Dr. Martin is the former president of the College of Naturopathic Physicians of British Columbia (CNPBC). Dr. Martin specializes in chronic conditions such as cardiovascular disease and diabetes. He is also an expert in treating difficult (though common) problems such as obesity, infertility, and chronic fatigue. He is also a specialist in menopause, hormonal dysfunction and other anti-aging modalities.
“The clinical research on cannabinoids has already captured the attention of health care practitioners, regulators, professional athletes and the media, which is why investors are so keenly interested in the industry,” said Phivida CEO JD Belfontaine. “One of the factors that sets Phivida apart is our unwavering support for research and education into this important field of health and wellness, and our commitment to apply what we learn to benefit families. Appointing our clinical advisory team is an important first step in that process.”
The advisory team convened at the A4M 25th World Congress, where Phivida launched its Vida+ product line – a clinical grade range of products for higher potency and are third party laboratory tested for cannabinoid potency, terpenes, residual solvents, bacteria and pesticides.
Phivida has officially listed and is now trading on the Canadian Securities Exchange under the CSE ticker symbol “VIDA.” For investor information please e-mail all requests to
Phivida Holdings Inc.
Phivida (pronounced “fi-VEE-da”) is a premier brand of cannabidiol (“CBD”)-infused functional foods, beverages and clinical products that is poised for global distribution. The World Anti-Doping Association’s recent decision to lift its ban of CBD from hemp oil and the World Health Organization’s recent statement supporting the clinical benefits of CBD open the door for athletes and active families use Phivida products. Phivida’s mission is to be a global leader in the alternative health sector while advancing education and research and investing back into our communities. For more information visit
For more information on Phivida visit or join our social media network @Phivida. For investor information please email us at


Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less